Loading…
TARO-MUPIROCIN is a brand name for Mupirocin, supplied as a ointment. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Serious Warnings and Precautions This mupirocin ointment formulation is not suitable for ophthalmic or intranasal use or use in conjunction with cannulae or at the site of venous cannulation. General When Taro-Mupirocin (mupirocin) is used on the face, care should be taken to avoid the eyes.
Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol based ointments, Taro-Mupirocin (mupirocin) should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.
Prescribing Taro-Mupirocin (mupirocin) in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria. Ear/Nose/Throat Taro-Mupirocin (mupirocin) is not suitable intranasal use.
Gastrointestinal Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhea during or after antibiotic use.
Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
Ophthalmologic Taro-Mupirocin (mupirocin) is not suitable for ophthalmic use. Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residue has been removed. Renal Moderate or severe renal impairment may occur upon absorption of large quantities of polyethylene glycol; please see General Information Section for further information.
Sensitivity/Resistance Use of topical antibiotics occasionally allows overgrowth of non-susceptible organisms. If this occurs, or irritation or sensitization develops, treatment should be discontinued and appropriate therapy instituted.
Sexual Function/Reproduction There are no data on the effects of mupirocin on human fertility. Studies in rats showed no effects on fertility (see PART II Non-Clinical Information). Taro-Mupirocin Product Monograph Page 5 of 28 Skin In the rare event of a possible sensitization reaction or severe local irritation occurring with the use of the product, treatment should be discontinued, the product should be wiped off and appropriate alternative therapy of the infection instituted.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Mupirocin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
As with other topical antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.
Special Populations Pregnant Women:
The safety of Taro-Mupirocin (mupirocin) in the treatment of infections during pregnancy has not been established. If administration to pregnant patients is considered necessary, its potential benefits should be weighed against the possible hazards to the fetus.
Studies in animals do not indicate reproductive toxicity (see PART II Non-Clinical Information).
Nursing Women:
There is no information on the excretion of mupirocin in milk. Caution should be exercised when Taro-Mupirocin (mupirocin) is administered to nursing mothers. If a cracked nipple is to be treated, it should be thoroughly washed prior to breastfeeding or manual expression.
If a treated cracked nipple is to be used for manual expression, milk from the affected breast should be discarded. The safety and efficacy of Taro-Mupirocin (mupirocin) during lactation has not been demonstrated in animal or human models.
ADVERSE REACTIONS Adverse Drug Reaction Overview Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), including isolated reports.
Common and uncommon adverse reactions were determined from pooled safety data from a clinical trial population of 1573 treated patients encompassing 12 clinical studies. Very rare adverse reactions were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than true frequency.
Immune system disorders:
Very rare: Systemic allergic reactions including anaphylaxis, urticaria, angioedema, and generalized rash have been reported with Taro-Mupirocin (mupirocin) Ointment.
Skin and subcutaneous tissue disorders:
Common: Burning localized to the area of application.
Uncommon:
Itching, erythema, stinging and dryness localized to the area of application.
Uncommon:
Cutaneous sensitization reactions to mupirocin or the ointment base. Taro-Mupirocin Product Monograph Page 6 of 28 Post-Market Adverse Drug Reactions Very Rare adverse events consist of systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of Taro- Mupirocin (mupirocin).
DRUG INTERACTION Serious Drug Interactions There are no known serious drug interactions noted for mupirocin. Overview There is no evidence of cross-resistance between mupirocin and other anti-microbial drugs. DOSAGE AND ADMINISTRATION Recommended Dose and Dosage Adjustment A small amount of Taro-Mupirocin (mupirocin) should be applied to cover the affected area 3 times daily for up to 10 days, depending on the response.
The area treated may be covered with a gauze dressing if desired. Always wash your hands before and after applying. Any product remaining at the end of treatment should be discarded. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin in the ointment.
Missed Dose If an application of Taro-Mupirocin (mupirocin) is missed, apply as soon as you remember or when it is convenient, and then continue as before.
Administration Populations Renal impaired:
See WARNINGS AND […]